Un-Audited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2025, along with the Auditors' Limited Review Reports in accordance with the provisions ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals reported its H1 FY26 (April–September 2025) numbers with revenue from operations falling about 20% year-on-year to Rs. 1,126.85 lakhs from Rs. 1,405.68 lakhs in H1 FY25. Total income (including other income) slipped to Rs. 1,405.08 lakhs from Rs. 1,470.85 lakhs. Profit before tax was Rs. 157.16 lakhs versus Rs. 167.16 lakhs a year ago, with profit after tax at Rs. 87.49 lakhs (a small dip versus the prior year). Despite the weaker top-line, the operating margin improved meaningfully, as total expenses were tightly controlled and finance costs stayed low. The company generated healthy operating cash flow of Rs. 301.83 lakhs during the half year and ended September 2025 with a debt-to-equity ratio of roughly 6%, indicating a clean balance sheet. Statutory auditor Shah Sanghvi & Associates issued an unqualified (clean) limited review report.
Mixed picture for shareholders — the sharp revenue drop is a clear red flag, but expanding margins, positive cash generation, low debt and a clean audit opinion cushion the blow. Expect a muted to slightly negative reaction unless the company signals a recovery path in coming quarters.